louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT00425958: Examination of Virtual Supermarket (Vmall) as an Assessment of Executive Functions in Children and Adolescents With Acquired Brain Injury
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Brain Injuries
Keywords: year and more after TBI
good vision
at least one functinal hand
cap[able od doing shopping during everyday life
Lead sponsor: Sheba Medical Center
Sponsor class: OTHER_GOV
First posted: 2007-01-24
Enrollment: 40
Sex: ALL
Minimum age (years): 8
Maximum age (years): 16
Standard ages: CHILD
Accepts healthy volunteers: yes
Time perspective: OTHER

Brief summary: The purpose of this research is to find whether or not there are differences in the executive functions during "shopping" in a "virtual mall", between children with Acquired Brain Injury (ABI) vs healthy children.

The hypothesis is that there will be differences in time (more time to shop) and mistakes (more mistakes during shopping), in the ABI group.


Eligibility criteria: Inclusion Criteria:

* children with ABI
* at least a year after injury
* who have been discharged from hospital and back home

Exclusion Criteria:

* children with learning disabilities former to injury
* visual disabilities or developmental disabilities

Primary outcomes:
Secondary outcomes:
Other outcomes:
Locations:
city: Ramat Gan
country: Israel
facility: Sheba Medical Center
Study officials:
affiliation: Sheba Medical Center
name: Amichai Brezner, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT02049658: The Sensitivity and Specificity of Sniff Dog as a Tool in Diagnosing the Suspected Tumor Patients
Official title: The Sensitivity and Specificity of Sniff Dog as a Tool in Diagnosing the Suspected Tumor Patients
Study type: OBSERVATIONAL
Overall status: RECRUITING
Conditions: Neoplasia
Keywords: tumor
cancer
Lead sponsor: Central South University
Sponsor class: OTHER
First posted: 2014-01-30
Enrollment: 2000
Sex: ALL
Minimum age (years): 1
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: * Healthy volunteers who have been examined by the currently used procedures and find to be without tumors.
* Patients in the breast surgery, thoracic surgery, gynecological and neurosurgery departments with lesions with characteristics of tumors

Brief summary: Previous studies have demonstrated that sniff dogs can identify cancer patients from healthy subjects through sniffing exhaled breath air or blood or serum or urine or feces. It is hypothesized that sniff dogs may be used as a tool in identifying cancer patients in the high risk population or suspected patients. Trained dogs will sniff serum from participants who are suspected to suffer from tumor by their physicians and not yet but will be diagnosed by pathological examination.The results will be compared with the outcome of the pathological examination.


Eligibility criteria: Inclusion Criteria:

* Healthy volunteers who have been examined by the currently used procedures and find to be without tumors.
* Patients in the breast surgery, thoracic surgery, gynecological and neurosurgery departments with lesions with characteristics of tumors

Exclusion Criteria:

* Patients who have had pathological results

Primary outcomes:
measure: sensitivity and specificity of the sniff dogs as a tool in diagnosing tumors
timeFrame: 12 months
Secondary outcomes:
measure: behavior patterns of the sniff dogs to different diseases
timeFrame: 12 months
Other outcomes:
measure: the substances used for identifying tumors by the sniff dogs
timeFrame: 12 months
Locations:
city: Changsha
country: China
facility: Center for Scientific Research with Animal Models, CSU
state: Hunan
Study officials:
affiliation: Central South University
name: Chang-Qing Gao, MD PhD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT01075958: Polyunsaturated Fatty Acids (PUFA) Status and Cognitive Function in Healthy Young Adults
Official title: The Relationship Between Serum PUFAs and Cognitive Function in Healthy Young Adults
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Attention
Memory
Mood
Mental Fatigue
Keywords: n-3 PUFAs
Fish oil
Cognitive function
Healthy young adults
Lead sponsor: Northumbria University
Sponsor class: OTHER
First posted: 2010-02-25
Enrollment: 283
Sex: ALL
Minimum age (years): 18
Maximum age (years): 35
Standard ages: ADULT
Accepts healthy volunteers: yes
Time perspective: CROSS_SECTIONAL
Sampling method: NON_PROBABILITY_SAMPLE
Study population: The sample will be drawn from a student and professional population in the Newcastle upon Tyne area in the UK

Brief summary: To date, the relationship between omega-3 polyunsaturated fatty acids (n-3 PUFAs) in cognitively intact individuals has only been examined in a limited number of studies; it is at present unknown whether supplementation with n-3 PUFAs can improve cognitive function and mood in this population. Further to this, it still remains to be established whether a relationship exists between peripheral fatty acid status-reflective of dietary n-3 PUFA intake-and cognitive function in this population. The current study therefore aims to address this issue by exploring the relationship between serum PUFAs and specific cognitive functions in a sample of healthy adults. To this end, participants will complete a range of cognitive tasks evaluating performance across the domains of attention, memory and executive function. Self-report mood assessments will be included as secondary measures.


Eligibility criteria: Inclusion Criteria:

* Male/Female
* 18-35 years
* Healthy
* No herbal supplements/prescription medications (excl. contraceptive pill)
* Non smoker
* Native English speaker

Exclusion Criteria:

* BMI ≥ 30

Primary outcomes:
measure: Simple Reaction Time (Attention)
timeFrame: Single visit
measure: Choice Reaction Time (Attention)
timeFrame: Single visit
measure: Four Choice Reaction Time (Attention)
timeFrame: Single visit
measure: Numeric Working Memory (Working Memory)
timeFrame: Single visit
measure: Alphabetic Working Memory (Working Memory)
timeFrame: Single visit
measure: Corsi Blocks Span (Spatial Working Memory)
timeFrame: Single visit
measure: 3-back Task (Working Memory)
timeFrame: Single visit
measure: Immediate Word Recall (Episodic Memory)
timeFrame: Single visit
measure: Delayed Word Recall (Episodic Memory)
timeFrame: Single visit
measure: Word Recognition (Episodic Memory)
timeFrame: Single visit
Secondary outcomes:
measure: Depression, Anxiety and Stress Scale (DASS)
timeFrame: Single visit-90 minutes
Other outcomes:
Locations:
city: Newcastle upon Tyne
country: United Kingdom
facility: Northumbria University
state: Tyne and Wear
Study officials:
affiliation: Northumbria University
name: Philippa A Jackson
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT01337258: Economic Analyses of the REDUCE Trial
Official title: Economic Analyses Alongside the REDUCE Clinical Trial
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Neoplasms, Prostate
Benign Prostatic Hyperplasia
Cancer
Keywords: cost effectiveness
dutasteride
elevated risk population
Prostate cancer
prevention
Lead sponsor: GlaxoSmithKline
Sponsor class: INDUSTRY
First posted: 2011-04-18
Enrollment: 1
Sex: MALE
Minimum age (years): 50
Maximum age (years): 75
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: RETROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: Men at increase risk for prostate cancer ages 50-75 who were enrolled in the REDUCE study

Brief summary: The objective of this project is to conduct a retrospective economic analysis of the use of dutasteride for the prevention of prostate cancer based on data from the REDUCE clinical trial. REDUCE is a 4-year, phase 3, randomized, double-blind, parallel assignment clinical trial of the use of dutasteride compared with no chemopreventive treatment.

The REDUCE trial was a four-year, international, multicenter, randomized, double-blind, placebo-controlled, parallel group study. There were 790 investigators in 42 countries.


Eligibility criteria: Inclusion Criteria:

* Men aged 50 to 75 years
* serum prostate-specific antigen (PSA) ≥2.5 ng per milliliter and ≤10 ng per milliliter (men aged 50-60 years) or ≥3.0 ng per milliliter and ≤10 ng per milliliter (men aged \>60 years)
* single, negative prostate biopsy (6-12 cores) within 6 months prior to enrollment (independent of the study)

Exclusion Criteria:

* Principal exclusion criteria were more than one prior prostate biopsy
* high-grade intraepithelial neoplasia (HG-PIN) or atypical small acinar proliferation (ASAP) on the pre-entry prostate biopsy
* a prostate volume \>80 ml, previous prostate surgery
* International Prostate Symptom Score (IPSS) ≥25 or ≥20 if already on alpha-blocker therapy for BPH

Primary outcomes:
measure: Cost of treating prostate-related events
timeFrame: REDUCE clinical trial, 4 year time period
Secondary outcomes:
Other outcomes:
Locations:
Study officials:
affiliation: GlaxoSmithKline
name: GSK Clinical Trials
role: STUDY_DIRECTOR
References:
Clinical trial NCT03654196: A Clinical Trial to Evaluate the Efficacy and Safety of HL301 Versus Umkamin Tab in Acute Bronchitis Patients
Official title: A Multicenter, Randomized, Double-blinded, Active-controlled, Parallel, Phase III Clinical Trial to Evaluate the Efficacy and Safety of HL301 Versus Umkamin Tab. in Acute Bronchitis Patients
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE3
Conditions: Acute Bronchitis
Keywords: Acute Bronchitis
Lead sponsor: Hanlim Pharm. Co., Ltd.
Sponsor class: INDUSTRY
First posted: 2018-08-31
Enrollment: 246
Sex: ALL
Minimum age (years): 19
Maximum age (years): 80
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: A Multicenter, Randomized, Double-blinded, Active-controlled, Parallel, Phase III Clinical Trial to Evaluate the Efficacy and Safety of HL301 versus Umkamin tab. in acute bronchitis patients

Endpoint: BSS, The improvement and improvement rate of the tester for the treatment response, The satisfaction of the subject


Eligibility criteria: Inclusion Criteria:

1. Both gender, 19 years ≤ age ≤ 80 years
2. (Bronchitis Severity Score)\* ≥ 5point at Visit 2 (Randomized Visit)
3. Acute bronchitis within 48hr based on Visit 2 (Randomized Visit)
4. Those who can comply with the requirements of clinical trials
5. Written consent voluntarily to participate in this clinical trial

Exclusion Criteria:

1. Patients with respiratory and systemic infections requiring systemic antibiotic therapy
2. Patients with bleeding tendency
3. Patients who investigators determines to severe respiratory disease that would interfere with study assessment
4. Patients who were treated with oral systemic adrenocortical hormone or immunosuppressive drug within 4 weeks prior to Visit 2
5. Patients who were treated with oral antihistamines, ACE suppressive. or systemic/inhalative glucocorticosteroid within 2 weeks prior to Visit 2

Primary outcomes:
measure: Bronchitis Severity Total Score(BSS) Change
timeFrame: Visit 1 (-3 day), Visit 2 (0 day), Visit 3 (7 day)
Secondary outcomes:
measure: The improvement and improvement rate of the tester for the treatment
timeFrame: Visit 3 (7 day)
measure: The satisfaction of the subject (Questionnaire)
timeFrame: Visit 3 (7 day)
Other outcomes:
Locations:
city: Seoul
country: Korea, Republic of
facility: Kyung Hee University Hospital
state: Dongdaemun-gu
Study officials:
References:
Clinical trial NCT05302258: Attenuation Imaging in Hepatic Steatosis
Official title: Noninvasive Assessment of Hepatic Steatosis by Using Attenuation Imaging in Children
Study type: OBSERVATIONAL
Overall status: UNKNOWN
Conditions: Hepatic Steatosis
Obesity, Childhood
Ultrasonography
Lead sponsor: Hallym University Kangnam Sacred Heart Hospital
Sponsor class: OTHER
First posted: 2022-03-31
Enrollment: 120
Sex: ALL
Minimum age (years): 5
Maximum age (years): 17
Standard ages: CHILD
Accepts healthy volunteers: yes
Observational model: CASE_CONTROL
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Obese and normal-weight children

Brief summary: For obese and normal-weight children, the investigators assess the diagnostic performance of attenuation imaging (ATI) in the detection of hepatic steatosis in children.


Eligibility criteria: Inclusion Criteria:

* BMI of 85th percentile or less

Exclusion Criteria:

* congenital anomaly including heart, intestine, kidney
* acute hepatitis
* congenital hepatic anomaly

Primary outcomes:
measure: Diagnostic performance of attenuation imaging
timeFrame: through study completion, an average of 1 year
Secondary outcomes:
Other outcomes:
Locations:
Study officials:
References:
Clinical trial NCT01919658: Effects of Femoral vs Saphenous Nerve Blocks on Function After ACL Repair
Official title: Effects of Femoral Versus Saphenous Nerve Blocks on Knee Extensor Strength, Pain, and Patient-Perceived Physical Function Following ACL Reconstruction
Study type: INTERVENTIONAL
Overall status: TERMINATED
Phase: NA
Conditions: Anterior Cruciate Ligament
Keywords: nerve blocks in Anterior cruciate ligament surgery
Lead sponsor: Milton S. Hershey Medical Center
Sponsor class: OTHER
First posted: 2013-08-09
Enrollment: 12
Sex: ALL
Minimum age (years): 18
Maximum age (years): 65
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The primary objective of the study is to compare motor strength in knee extension between two groups of patients. One group receiving a proximal thigh block of the femoral nerve, and one receiving a distal thigh block of the saphenous nerve. The secondary objective is to compare the pain relief and functional outcomes in these two groups.


Eligibility criteria: Inclusion Criteria:

1. Age 18-65
2. Upcoming ACL reconstruction using patellar tendon autograft scheduled at Hershey Medical Center or the Hershey Outpatient Surgical Center (HOSC)

Exclusion Criteria:

1. Documented neuropathy
2. Skeletally immature
3. Previous knee surgery
4. Inability to provide informed consent
5. ACL reconstruction with other tendon repairs

Primary outcomes:
measure: strength of knee extensors
timeFrame: change from baseline preoperatively at 12 months
Secondary outcomes:
measure: pain level and functional outcomes
timeFrame: change from in hospital post-operative period at 12 months
Other outcomes:
Locations:
city: Hershey
country: United States
facility: Penn State Hershey Medical Center
state: Pennsylvania
Study officials:
affiliation: Milton S. Hershey Medical Center
name: Robert Gallo, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT04228796: Analysis of Biomarkers in Lymph Node Tissue
Official title: Analysis of Biomarkers in Lymph Node Tissue
Study type: OBSERVATIONAL
Overall status: ACTIVE_NOT_RECRUITING
Conditions: Analysis of Biomarkers in Lymph Node Tissue
Lead sponsor: Mayo Clinic
Sponsor class: OTHER
First posted: 2020-01-14
Enrollment: 200
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: CASE_ONLY
Time perspective: RETROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Analysis will be done on previously collected tissue of 200 adult subjects who underwent transplant surgery.

Brief summary: Researchers are doing an exploratory analysis of biomarkers to correlate with treatment outcome of transplant surgery.

Detailed description: Researchers will study previously collected tissue, which was sent for pathological examination, of 200 patients who underwent transplant surgery. Concentration of biomarkers in lymph node tissue will be measured.

Eligibility criteria: Inclusion Criteria:

* Adults (18+years of age)
* Undergo any organ transplant

Exclusion Criteria:

* Under the age of 18 years old

Primary outcomes:
measure: List of biomarkers
timeFrame: Baseline
Secondary outcomes:
Other outcomes:
Locations:
city: Jacksonville
country: United States
facility: Mayo Clinic in Florida
state: Florida
Study officials:
affiliation: Mayo Clinic
name: Antonio Forte, MD, PhD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT01548196: Standard Percutaneous Nephrolithotomy Percutaneous Nephrolithotomy (PNL) Versus Tubeless PNL Versus Tubeless Stentless PNL
Official title: A Prospective, Randomized Controlled Pilot Study Of Standard Percutaneous Nephrolithotomy (PNL) Versus Tubeless PNL Versus Tubeless Stentless PNL
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE3
Conditions: Nephrolithotomy
Keywords: nephrolithotomy
Lead sponsor: Duke University
Sponsor class: OTHER
First posted: 2012-03-08
Enrollment: 60
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The purpose of the study is to assess and compare the efficacy and morbidity standard percutaneous nephrolithotomy with tubeless PNL. A total of approximately 60 patients will be enrolled. Patients will be randomized to one of four groups: standard percutaneous nephrostomy, double-J ureteral stent, open-ended ureteral catheter and no nephrostomy or ureteral stent/catheter. Primary Outcome Measures will include length of procedure and estimated blood loss. Post-operative analgesic use (both parenteral and oral), pain scores, time to ambulation, time to oral intake, and pain scores will also be recorded. Time to nephrostomy tube removal, external ureteral and Foley catheter removal and patient discharge from the hospital will also be recorded. Incidence and type of post-operative complications will also be recorded.


Eligibility criteria: Inclusion Criteria:

* Age \>18 years old
* Planned single tract percutaneous nephrolithotomy
* General anesthesia for percutaneous nephrolithotomy

Exclusion Criteria:

* Age\<18 years old
* Known residual calculi at the end of the procedure
* Significant hemorrhage during procedure
* Bleeding disorder (This does not include patients taking anti-coagulants as these are stopped prior to surgery.)
* Prisoners
* Inability to give informed consent
* Pregnant females
* Solitary kidney
* Transplant kidney
* Pleural effusion during procedure requiring drainage
* Perforation of renal collecting system during procedure
* Incomplete stone clearance
* Chronic pain syndrome

Primary outcomes:
measure: Length of hospital stay
timeFrame: until hospital discharge, about 2-3 days
measure: Change in CBC and Chemistry Panel
timeFrame: at time of hospital discharge, about 2-3 days
Secondary outcomes:
Other outcomes:
Locations:
city: Durham
country: United States
facility: Duke University Medical Center
state: North Carolina
Study officials:
affiliation: Duke University
name: Glenn Preminger, M.D.
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT03219996: Risk Factors for Predictors of In-hospital Death in Acute Fulminant Myocarditis
Official title: Risk Factors Influenced Prognosis of Acute Fulminant Myocarditis by Analyzing Clinical Characteristics and Complications, Laboratory Findings, Treatments, and Electrocardiographic and Echocardiographic Data.
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Viral Myocarditis
Cardio-Renal Syndrome
Risk Factor, Cardiovascular
Lead sponsor: The First Affiliated Hospital of Soochow University
Sponsor class: OTHER
First posted: 2017-07-18
Enrollment: 76
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: CASE_CONTROL
Time perspective: RETROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: The definition of a fulminant acute myocarditis was the presence of a rapid onset of aggressive life-threatening disease accompanied by cardiogenic shock with multiple organ dysfunction syndrome, acute severe heart failure, fatal arrhythmias, high-degree atrioventricular blockade, or sudden cardiac death following a flu-like illness.

Brief summary: The investigators performed a retrospective, single-center observational study, and the participants with acute fulminant myocarditis were included.Then, the investigator analyzed the risk factors of in-hospital death in these participants with acute fulminant myocarditis.


Eligibility criteria: Inclusion Criteria:

Clinical diagnosis of acute fulminant myocarditis

Exclusion Criteria:

chronic renal dysfunction refuse medical treatments

Primary outcomes:
measure: Renal Impairment Influence Prognosis of Acute Fulminant Myocarditis
timeFrame: 2017-01-30
Secondary outcomes:
Other outcomes:
Locations:
Study officials:
affiliation: First Affiliated Hospital of Soochow University
name: Xiangjun Yang, PhD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT06382896: Effect of Oliceridine on Rebound Pain
Official title: A Clinical Study on the Effect of Oliceridine（TRV130） on Postoperative Rebound Pain and Early Rehabilitation Exercise After Knee Arthroscopy
Study type: OBSERVATIONAL
Overall status: RECRUITING
Conditions: Rebound Pain
Arthroscopic Knee Surgery
Oliceridine
Lead sponsor: The First Affiliated Hospital of Xiamen University
Sponsor class: OTHER
First posted: 2024-04-24
Enrollment: 320
Sex: ALL
Minimum age (years): 18
Maximum age (years): 70
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: RETROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: General anesthesia combined with femoral nerve block was selected for knee arthroscopic day surgery

Brief summary: The purpose of this clinical study was to identify the risk factors for postoperative pain outburst in patients undergoing arthroscopic knee surgery after Oliceridine and nerve block, and to evaluate the effect of oxeridine on early rehabilitation exercise in patients. A total of 320 patients undergoing arthroscopic knee arthroscopy under general anesthesia combined with femoral nerve block were selected to record the time and duration of postoperative pain outbreak, pain degree, age, gender, operation type, previous surgical history and other related risk factors.


Eligibility criteria: Inclusion Criteria:

1. Age 18-70 years old;2. Body mass index (BMI) 18-30kg /m2;3. American Society of Anesthesiologists (ASA) Grade I to II;4. Hospital stay \>24h.

Exclusion Criteria:

1. Patients who cannot understand the numerical rating scale score and give feedback;2. Known allergy to the drug in the study;3. Infection of puncture site with nerve block;4. Oral analgesics for more than 2 weeks before surgery;5. Long-term use of glucocorticoids;6. Simultaneous surgery on both limbs;7. A psychopath;8. Severe compound trauma;9. Pregnant and lactating women.

Primary outcomes:
measure: Time of onset of postoperative rebound pain
timeFrame: Within 48 hours after surgery
measure: The duration of the rebound pain
timeFrame: Within 48 hours after surgery
measure: The degree of the rebound pain
timeFrame: Within 48 hours after surgery
measure: age
timeFrame: Within 48 hours after surgery
measure: sex
timeFrame: Within 48 hours after surgery
measure: Surgical procedure
timeFrame: Within 48 hours after surgery
measure: Previous surgical history
timeFrame: Within 48 hours after surgery
Secondary outcomes:
measure: Movement recovery time
timeFrame: Within 7 days of surgery
Other outcomes:
Locations:
city: Xiamen
country: China
facility: First Affiliated Hospital of Xiamen University
state: Fujian
Study officials:
References: